Author

G. Ferron

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Coste· 1 shared A. Le Naour· 1 shared A. Martinez· 1 shared B. Bui· 1 shared B. Couderc· 1 shared B. Thibault· 1 shared C. Chevreau· 1 shared C. Merle· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Coste

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Distinct cellular origins and differentiation process account for distinct oncogenic and clinical behaviors of leiomyosarcomas

E. Darbo, G. Perot, L. Darmusey, S. Le Guellec, L. Leroy, L. Gaston, N. Desplat, N. Thebault, C. Merle, P. Rochaix, T. Valentin, G. Ferron, C. Chevreau, B. Bui, E. Stoeckle, , F. Chibon

The paper identifies a transcriptionally homogeneous subgroup of leiomyosarcomas originating from vascular smooth muscle cells and explains their unique oncogenic behavior through specific pathway alterations.

bioRxiv · Oct 23, 2020Cancer Biology

Mesenchymal stromal cells release CXCL1/2/8 and induce chemoresistance and macrophage polarization

B. Couderc, A. Le Naour, M. Prat, R. Mevel, B. Thibault, L. Lemaitre, H. Leray, M. Golzio, L. Lefevre, E. Mery, A. Martinez, G. Ferron, J.-P. Delord, A. Coste

This study identifies CXCL1/2/8 as factors released by cancer-associated mesenchymal stromal cells that induce chemoresistance and macrophage polarization, suggesting CXCR1/2 inhibition as a potential therapeutic strategy.

bioRxiv · Dec 4, 2018 · PreprintCancer Biology